Scopus Biopharma 55336VAL4 Bond
SCPSDelisted Stock | USD 0.10 0.00 0.00% |
Scopus Biopharma holds a debt-to-equity ratio of 0.613. . Scopus Biopharma's financial risk is the risk to Scopus Biopharma stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Scopus Biopharma's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Scopus Biopharma's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the OTC Stock is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Scopus OTC Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Scopus Biopharma's stakeholders.
For most companies, including Scopus Biopharma, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Scopus Biopharma, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Scopus Biopharma's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Scopus |
Given the importance of Scopus Biopharma's capital structure, the first step in the capital decision process is for the management of Scopus Biopharma to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Scopus Biopharma to issue bonds at a reasonable cost.
Popular Name | Scopus Biopharma MPLX LP 52 |
Specialization | Biotechnology |
Equity ISIN Code | US8091711015 |
Bond Issue ISIN Code | US55336VAL45 |
S&P Rating | Others |
Maturity Date | 1st of March 2047 |
Issuance Date | 10th of February 2017 |
Coupon | 5.2 % |
Scopus Biopharma Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Volcan Compania Minera | USP98047AC08 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
HSBC Holdings PLC | US404280DR76 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details |
Understaning Scopus Biopharma Use of Financial Leverage
Scopus Biopharma's financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Scopus Biopharma's current equity. If creditors own a majority of Scopus Biopharma's assets, the company is considered highly leveraged. Understanding the composition and structure of Scopus Biopharma's outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York. Scopus Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people. Please read more on our technical analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Scopus OTC Stock
If you are still planning to invest in Scopus Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Scopus Biopharma's history and understand the potential risks before investing.
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Stocks Directory Find actively traded stocks across global markets | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.